ZLDPF (Zealand Pharma AS) Total Assets: $2,367 Mil (As of Mar. 2026)


ZLDPF Zealand Pharma AS ZLDPF
62 GF Score
Price $42.11
GF Value $1,929.01
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Zealand Pharma AS Total Assets?

Zealand Pharma AS ZLDPF -1.82% 62 Total Assets is $2,367 Mil as of Mar. 2026. GuruFocus rates ZLDPF with a GF Score™ of 62/100 and a GF Value™ of $1,929.01 (Possible Value Trap). The stock has 3 warning signs investors should review.

Zealand Pharma AS's Total Assets for the quarter that ended in Mar. 2026 was $2,367 Mil.

During the past 12 months, Zealand Pharma AS's average Total Assets Growth Rate was 44.20% per year. During the past 3 years, the average Total Assets Growth Rate was 32.40% per year. During the past 5 years, the average Total Assets Growth Rate was 14.00% per year. During the past 10 years, the average Total Assets Growth Rate was 21.50% per year.

During the past 13 years, Zealand Pharma AS's highest 3-Year average Total Assets Growth Rate was 117.00%. The lowest was -31.30%. And the median was 26.70%.

Total Assets is connected with ROA %. Zealand Pharma AS's annualized ROA % for the quarter that ended in Mar. 2026 was -10.02%. Total Assets is also linked to Revenue through Asset Turnover. Zealand Pharma AS's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Zealand Pharma AS  (OTCPK:ZLDPF) Total Assets Explanation

Total Assets is connected with ROA %.

Zealand Pharma AS's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-243.764/( (2500.439+2366.634)/ 2 )
=-243.764/2433.5365
=-10.02 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Zealand Pharma AS's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=5.259/( (2500.439+2366.634)/ 2 )
=5.259/2433.5365
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Zealand Pharma AS Total Assets Related Terms

Zealand Pharma AS Total Assets Historical Data

* Premium members only.

The historical data trend for Zealand Pharma AS's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma AS Total Assets Chart

Zealand Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 314.18 219.26 289.69 1,334.66 2,500.44

Zealand Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,322.20 2,656.16 2,641.49 2,500.44 2,366.63
ZLDPF
62GF Score
Zealand Pharma AS ZLDPF
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zealand Pharma AS Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Zealand Pharma AS's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=2325.131+175.308
=2,500

Zealand Pharma AS's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=2237.947+128.687
=2,367

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $2,367 Mil mean?
Zealand Pharma AS (ZLDPF) has a Total Assets of $2,367 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Zealand Pharma AS and its competitors.
Is Zealand Pharma AS's Total Assets too high?
Zealand Pharma AS's current Total Assets is $2,367 Mil. Overall, Zealand Pharma AS has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Total Assets compare to VRTX and REGN?
Zealand Pharma AS's Total Assets of $2,367 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Zealand Pharma AS and its competitors. Zealand Pharma AS's current Total Assets is $2,367 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $1,929.01, compared to a current price of $42.11 — trading 97.8% below its estimated fair value. The current Total Assets is $2,367 Mil. Zealand Pharma AS's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current Total Assets is $2,367 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of $42.11 is trading 97.8% below its estimated GF Value™ of $1,929.01. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for ZLDPF:

  • Total Assets: $2,367 Mil
  • GF Value™: $1,929.01 vs. price of $42.11 (97.8% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
62GF Score

Get the complete analysis for ZLDPF

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.11
Price
$1,929.01
GF Value